Targeting challenging integrin protein
Not specified
DiscoveryActive
Key Facts
About Receptor.ai
Receptor.ai is a private, pre-revenue AI-native biotechnology company offering an end-to-end computational drug discovery platform. Its core technology is a modular, agentic AI-driven ecosystem with three distinct platforms for small molecules, peptides, and proximity inducers, each designed to tackle specific modality challenges like cryptic pocket targeting and multiparametric optimization. The company operates a platform/services business model, partnering with biopharma clients to generate novel, IP-free drug candidates, as evidenced by its published case studies, though it does not appear to have an internal therapeutic pipeline advancing through clinical trials.
View full company profileOther Not specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |